Denmark · Delayed Price · Currency is DKK Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of DKK 22.92 billion. The enterprise value is 8.87 billion.
| Market Cap | 22.92B |
| Enterprise Value | 8.87B |
Important Dates
The next confirmed earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zealand Pharma has 70.24 million shares outstanding. The number of shares has increased by 4.13% in one year.
| Current Share Class | 70.24M |
| Shares Outstanding | 70.24M |
| Shares Change (YoY) | +4.13% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | 30.23% |
| Float | 56.33M |
Valuation Ratios
The trailing PE ratio is 3.65 and the forward PE ratio is 19.08.
| PE Ratio | 3.65 |
| Forward PE | 19.08 |
| PS Ratio | 2.48 |
| PB Ratio | 1.58 |
| P/TBV Ratio | 1.59 |
| P/FCF Ratio | 3.62 |
| P/OCF Ratio | 3.60 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.30, with an EV/FCF ratio of 1.40.
| EV / Earnings | 1.39 |
| EV / Sales | 0.96 |
| EV / EBITDA | 1.30 |
| EV / EBIT | 1.31 |
| EV / FCF | 1.40 |
Financial Position
The company has a current ratio of 37.17, with a Debt / Equity ratio of 0.03.
| Current Ratio | 37.17 |
| Quick Ratio | 36.40 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.07 |
| Interest Coverage | 260.34 |
Financial Efficiency
Return on equity (ROE) is 56.16% and return on invested capital (ROIC) is 2,303.69%.
| Return on Equity (ROE) | 56.16% |
| Return on Assets (ROA) | 34.72% |
| Return on Invested Capital (ROIC) | 2,303.69% |
| Return on Capital Employed (ROCE) | 45.54% |
| Weighted Average Cost of Capital (WACC) | 7.46% |
| Revenue Per Employee | 16.99M |
| Profits Per Employee | 11.76M |
| Employee Count | 544 |
| Asset Turnover | 0.76 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zealand Pharma has paid 547.06 million in taxes.
| Income Tax | 547.06M |
| Effective Tax Rate | 7.88% |
Stock Price Statistics
The stock price has decreased by -45.14% in the last 52 weeks. The beta is 0.59, so Zealand Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -45.14% |
| 50-Day Moving Average | 306.31 |
| 200-Day Moving Average | 405.33 |
| Relative Strength Index (RSI) | 54.89 |
| Average Volume (20 Days) | 503,637 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of DKK 9.24 billion and earned 6.40 billion in profits. Earnings per share was 89.42.
| Revenue | 9.24B |
| Gross Profit | 9.24B |
| Operating Income | 6.78B |
| Pretax Income | 6.94B |
| Net Income | 6.40B |
| EBITDA | 6.80B |
| EBIT | 6.78B |
| Earnings Per Share (EPS) | 89.42 |
Balance Sheet
The company has 14.47 billion in cash and 414.00 million in debt, with a net cash position of 14.05 billion or 200.09 per share.
| Cash & Cash Equivalents | 14.47B |
| Total Debt | 414.00M |
| Net Cash | 14.05B |
| Net Cash Per Share | 200.09 |
| Equity (Book Value) | 14.47B |
| Book Value Per Share | 204.77 |
| Working Capital | 14.61B |
Cash Flow
In the last 12 months, operating cash flow was 6.36 billion and capital expenditures -37.37 million, giving a free cash flow of 6.32 billion.
| Operating Cash Flow | 6.36B |
| Capital Expenditures | -37.37M |
| Depreciation & Amortization | 14.95M |
| Net Borrowing | -25.16M |
| Free Cash Flow | 6.32B |
| FCF Per Share | 90.03 |
Margins
Gross margin is 99.99%, with operating and profit margins of 73.41% and 69.21%.
| Gross Margin | 99.99% |
| Operating Margin | 73.41% |
| Pretax Margin | 75.13% |
| Profit Margin | 69.21% |
| EBITDA Margin | 73.58% |
| EBIT Margin | 73.41% |
| FCF Margin | 68.43% |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.13% |
| Shareholder Yield | -4.13% |
| Earnings Yield | 27.91% |
| FCF Yield | 27.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Zealand Pharma is 525.73, which is 108.38% higher than the current price. The consensus rating is "Buy".
| Price Target | 525.73 |
| Price Target Difference | 108.38% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | -50.39% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zealand Pharma has an Altman Z-Score of 24.53 and a Piotroski F-Score of 6.
| Altman Z-Score | 24.53 |
| Piotroski F-Score | 6 |